How does the new once-a-week insulin work, and who is it for?
Onswik is a weekly basal insulin approved for adults with type 2 diabetes. It is not approved for type 1 diabetes, and switching doses requires medical supervision.
Onswik (insulin efsitora) is a long-acting basal insulin approved for adults with type 2 diabetes. In trials involving more than 3,400 people, weekly dosing lowered A1C no worse than daily basal insulin. It will come in KwikPen formats, but it is not approved for type 1 diabetes and is not a do-it-yourself swap from a current insulin.
Ask the prescribing clinician about transition dosing, monitoring, missed-dose rules, and low-blood-sugar risk; diet and activity still matter.
Why weekly basal insulin changes the routine
Basal insulin provides background coverage between meals and overnight, and it is normally taken every day. A formulation designed to release slowly and last much longer can reduce that routine to one weekly injection for some adults with type 2 diabetes. Fewer injections may suit some people's schedules, but longer action also means dose changes take longer to settle.
What to do, step by step
- Confirm who it is approved for: adults with type 2 diabetes, not type 1.
- Understand that switching from a daily insulin requires a clinician-set transition dose.
- Ask how monitoring, missed doses, and low-blood-sugar risk are handled week to week.
- Keep diet, activity, and other medicines in the discussion, since they still matter.
Ask AI about this tip
Send this tip to your favorite AI assistant for a plain-language walkthrough, follow-up questions, or help applying it to your device.